Background: Serum vitamin D (VitD) status is associated with active tuberculosis (TB) and TB infection conversion (TBIC). Objectives: The objective of the present study was to quantify the risks of TB (latent, conversion, disease) in accordance with VitD status and other variables among the contacts of pulmonary TB patients. Methods: From 2009 to 2012, a cohort of the contacts of pulmonary TB patients was studied to rule out and prevent TB in Castellon (Spain). The exams performed included a tuberculin skin test (TST), a QuantiFERON Gold in-tube test® (QFTGIT), blood and radiographic tests, and an initial measurement of serum VitD status. Contacts who were initially without active TB were followed up through 2015. Multinomial logistic regression (MLR) analyses were carried out. Results: From a total of 572 contacts of pulmonary TB patients with VitD status measurement, 523 completed the follow-up (participation rate 91.4%). Among them, five groups could be established: 3 new cases of pulmonary TB (0.6%), 27 cases of TBIC (5.2%), 116 cases of latent TB infection (LTBI) (22.2%), 125 uninfected TB contacts with only one TST or QFTGIT measurement (23.9%), and 252 uninfected TB contacts with two TST or QFTGIT measurements (48.2%). The comparison of these five groups revealed several significant differences, including age, whether they were foreign-born, place of residence, social class, high exposure to an index case with sputum acid-fast bacilli (AFB), and VitD status. The MLR analysis for all groups, with the group of uninfected TB contacts with two TST or QFTGIT measurements as a reference, estimated that only two of these factors were significantly associated with TB in three or more groups; these factors were VitD status and high exposure and a sputum AFB-positive index case. VitD status was a protector against pulmonary TB with a relative risk (RR) of 0.86 (95% confidence interval [CI] 0.74 -0.99) and against TBIC (R = 0.95; 95% CI 0.91 -0.99), while it was not associated with LTBI (RR = 0.99; 95% CI 0.97-1.01). Only 34.0% of the contacts had sufficient VitD levels (≥ 30 ng/mL). Conclusions: Our results suggest that a sufficient VitD level could be a protective factor against TBIC and active TB.
Background
Serum vitamin D (VitD) status is considered a factor in the development of tuberculosis (TB) (1) . Low levels of VitD have been associated with an increase of pulmonary TB (2, 3) , and two prospective cohort studies of the contacts of pulmonary TB patients that considered VitD status have found this relationship (4, 5) . However, VitD supplements added to the standard treatments of pulmonary TB in several clinical trials have not been able to significantly eliminate Mycobacterium tuberculosis (M. tuberculosis) from the sputum of patients to date, though several clinical aspects have been improved (6) (7) (8) (9) (10) (11) (12) . Since VitD supplements have been indicated to prevent TB infection (13) , the first preventive clinical trial on Mongolian children was carried out with close to significant results (14) .
A cohort study of the contacts of pulmonary TB patients may allow for the quantification of the association of VitD status with TB disease, latent TB infection (LTBI), and TB infection conversion (TBIC), as we have already studied in recent publications (15) (16) (17) . In addition, an analysis of this cohort as a whole may be useful to obtain measurements of the association of VitD with other potential factors.
Objectives
The objective of this study was to quantify the risks of TB (latent, conversion, disease) in accordance with vitamin D status and other variables among contacts of pulmonary TB patients.
Methods

Study Design
Recruitment of participants included in the prospective cohort study of the contacts of pulmonary TB patients took place during 2009 -2012. Follow-up was carried out by the epidemiology division of the public health center of castellon and the preventive medicine department of the hospital La Plana of Vila-real and finished in 2015. The Vila-real area is situated at a latitude of 39°north on the Mediterranean coast of Spain, with a population of 470,000 inhabitants. The epidemiology division implemented the follow-up of the cohort through the permanent TB register and the population information system of the Valencian community health care system.
Tuberculosis Diagnostic Tests
In order to rule out and prevent TB, contacts were examined and a tuberculin skin test (TST) with 2 tuberculin units equivalent to 5IU of purified protein derivative RT-23 (PPD) from the serologic institute of Copenhagen and/or a QuantiFERON-TB Gold in-tube test (QFTGIT® Cellestis Limited), which is an interferon-gamma release assay, were administered. In addition to these tests, clinical, analytical, and thorax radiographic exams were performed. Moreover, all participants were interviewed about TB risk factors. A more detailed methodology has been reported in previous publications (15, 16) . For the participants, chemoprophylaxis against TB was recommended, taking into account exposure, age, clinical conditions, and the characteristics of the index TB case. The following definitions were used (18-20):
New Pulmonary TB
Diagnosis of TB based on laboratory tests and thorax radiographic exams, including determination of acid-fast bacilli (AFB) in sputum through smear microscopy and sputum culture of M. tuberculosis. The laboratory study was carried out by the microbiology laboratory of the hospital general of Castellon (HGC) and the hospital La Plana of Vilareal.
LTBI
A positive TST with induration size ≥ 5 mm when not vaccinated against Bacilli Calmette-Guerin (BCG) or ≥ 15 mm when BCG-vaccinated or a QFTGIT ≥ 0.35 IU/mL. In addition, clinical and radiographic exams were negative.
TBIC
Eight to ten weeks after the initial examination with negative TST, an increase of induration of 5 mm when non-BCG-vaccinated or 10 mm when BCG-vaccinated. For the QFTGIT analysis, the definition was the change from a negative < 35 IU/mL test to a positive test ≥ 35 IU/mL. Booster TST was indicated for contacts > 54 years old and/or BCGvaccinated when the initial TST was negative 7 days after the first TST. In addition, clinical and radiographic exams were negative.
On the basis of these definitions and the follow-up, five groups were studied: 1, new pulmonary TB patients; 2, TBIC patients; 3,LTBI patients; 4, uninfected TB contacts when only one TST or QFTGIT measurement was required (the date of study was greater than two months after exposure to the TB index case) or contacts without second TST or QFT-GIT measurements, and 5, uninfected TB contacts with two TST or QFTGIT measurements. (21, 22). An extra 10% of concentration of VitD was added for the patients studied by ECLIA, because the ECLIA technique measures only D3 and not D2. Supplements of VitD were recommended for contacts with insufficient VitD levels (< 30 ng/mL).
Vitamin D Determinations
Ethical Issues
The Ethics Committee of the HGC approved the study, and signed consent was obtained from all participants or their parents. Children under the age of 10 years were not included in the study.
Statistical Analysis
The five groups were compared using the Chi2 and Fisher tests for qualitative variables and the Kruskal-Wallis test for quantitative variables. Multinomial logistic regression (MLR) models were used in order to quantify the relative risk (RR) of the five groups (dependent variables) in accordance with different independent variables, taking the 2 Avicenna J Clin Microb Infec. 2017; 4(1):e36889.
group uninfected with TB and with two TST or QFTGIT measurements as the reference group. Two MLRs were implemented, with the first considering the two first groups and the second including the two remaining groups, using the last group as a reference in all cases. All MLR models meet the property of independence from irrelevant alternatives following the generalized Hausman specification test (23) . The Stata® program version 12.0 was used for the statistical analysis.
Results
During the study period, 836 contacts of pulmonary TB patients were screened, and 572 who had serum VitD determinations were included in the study. Among them, 523 (91.4%) completed the follow-up and were divided into five contact groups (Table1): 1) 3 (0.6%) new pulmonary TB patients with a positive M. tuberculosis sputum culture; 2) 27 (5.2%) TBIC patients; 3) 125 (23.9%) LTBI patients; 4) 116 (22.2%) uninfected TB contacts when only a TST or a QFTGIT was required (41 contacts) or contacts without a second TST or QFTGIT determination (75 contacts); and 5) 252 (48.2%) uninfected TB contacts with two TST or QFTGIT measurements. Table 1 shows the characteristics of the groups. Values for age, residence in Vila-real, and social class III-VI were higher in the new pulmonary TB patients; the foreign-born group had higher proportions of TBIC patients. The mean of VitD was lower for the new pulmonary TB patients, and the higher value corresponded to the group of uninfected TB contacts with two TST or QFTGIT measurements. This last group had the highest proportion (38.1%) of contacts with sufficient VitD levels (≥ 30 ng/mL); only 14.8% of the TBIC patients and 0% of the new pulmonary TB patients had sufficient levels. Among all participants, the prevalence of sufficient, deficient (< 20 ng/mL), and very deficient (< 10 ng/mL) VitD levels was 34.0%, 24.9% and 7.8%, respectively. The new pulmonary TB patients had the highest exposure and a sputum AFB-positive index case. Other variables, including BCG vaccination, BMI, diabetes mellitus, current smoker, and study period were not associated with the groups. Chemoprophylaxis was recommended for 84 contacts (14.7%).
The MLR (Table 2 ) included all groups, with the uninfected TB contacts with two TSTs or QFTGITs group as the reference. VitD status and high exposure and a sputum AFBpositive index case were significantly associated with three or more groups, while VitD status was a significant protector against new pulmonary TB (RR = 0.86; 95% CI 0.74 -0.99) and TBIC (RR = 0.95; 95% CI 0.91 -0.99). Pulmonary TB and TBIC risks were reduced by 14% and 5% by an increase of 1 ng/mL of VitD, respectively. The combination of high exposure and a sputum AFB-positive index case was associated with pulmonary TB disease, TBIC, and LTBI. However, VitD status was not associated with LTBI (RR = 0.99; 95% CI 0.97-1.01).
An MLR model considering only the three groups of pulmonary TB, TBIC, and uninfected TB contacts with two TSTs or QFTGITs was carried out (Table 3) ; VitD status was a protective factor against pulmonary TB and TBIC. Male gender and being foreign-born were risk factors for TBIC (RR = 3.04; 95% CI 1.22 -7.59 and RR = 2.62; 95% CI 1.07 -6.40, respectively). The combination of high exposure and a sputum AFB-positive index case was a high risk factor.
Significant differences were found when the LTBI patients and uninfected TB with one TST or QFTGIT measurement groups were compared with the reference group (Table 4). The LTBI patients group was older, included more current smokers, and had an increase in high exposure and sputum AFB-positive index cases; Vila-real residence was a protective factor. VitD status was not associated with LTBI. In the uninfected TB contacts with one TST or QFTGIT measurement group, VitD status and Vila-real residence were a protective factor.
Discussion
In this study, we have found VitD status as a protective factor against pulmonary TB and TBIC, but not for LTBI. Considering all variables, the variables associated with TB in three groups were a high exposure sputum AFB-positive index case and VitD status. In this cohort, the incidence of pulmonary TB was higher than other studies, but the frequency of TBIC and LTBI were lower; on the other hand, the number of cases lost to follow-up was low (24) (25) (26) .
Variables such as age, male gender, foreign birthplace, social class, malnutrition, being a current smoker, and season have been associated with TB in different studies (27) (28) (29) (30) (31) . However, in the MLR models, these factors lost significance, suggesting that VitD status is strongly associated with TB outcomes. In more restricted comparisons, male gender and foreign birthplace were associated with TBIC, whereas age and being a current smoker were associated with LTBI.
Few studies have explored VitD status before the development of TBIC or TB disease. These include a clinical trial in Mongolian children on TBIC (14), a study of TB disease in Pakistan (4), and another study in Africa with HIV patients (15) . In these studies, low VitD levels were associated with an increase of TB. Studies on active TB patients suggested that low VitD status is a risk factor for the disease (32) (33) (34) .
We have found that the prevalence of LTBI was not associated with VitD status. Serum VitD status can vary with the seasons of the year, and the onset of LTBI may be prior to the studied TB exposure. In addition, LTBI may require sufficient VitD levels to have antimicrobial activity against M. tuberculosis in order to prevent active TB (35) , and other unknown factors apart from VitD could play a role in TB development (36).
VitD plays an important role in innate and adaptive immunity protection against TB. Multiple cells, receptors, cytokines, and antimicrobial peptides such as cathelicidin and defensin beta 4 have been implicated in these complex mechanisms (37) (38) (39) (40) (41) . In this context, a sufficient VitD level at the time of M. tuberculosis exposure could be crucial to obtain an adequate protection against TBIC, together with an optimal nutritional status (42).
It should be noted that the prevalence of very deficient and deficient VitD status (< 30 ng/mL) was high, considering the localization of Castellon and the Mediterranean climate. This is in line with some studies performed in Spain, which have found a high prevalence of deficient levels of VitD in several populations (43) (44) (45) .
Turning to the strengths of this study, we highlight its prospective design, an acceptable participation and follow-up rate, contacts with exposure to pulmonary TB, validated techniques of VitD measurement, and the two methods to test the TB situation, namely the TST and the QFTGIT.
In terms of the study limitations, these include the lack of VitD receptor polymorphisms genotyping and the use of only one determination of VitD with two different techniques. Among the TB risk factors, measurements that are more precise, such as poverty or crowding, could have been used. In addition, the sample of new pulmonary TB patients was small.
On the other hand, the measurement of TBIC has some complexity for the TST and the QFTGIT (46, 47) , and the VitD status determination presents technical problems in relation to the carrier, the vitamin D binding protein, and the standardization (48) . One direction for future research into the effect of VitD on TB incidence (TBIC or disease) would be to introduce a new measurement of VitD at the time of the second screening for TB control.
Determining VitD status among the contacts of TB patients could be useful to evaluate the risk of TB development, and VitD supplements could be recommended if a VitD deficiency is found, considering the high prevalence of deficient levels and their relationship to TB. Two preventive clinical trials have been proposed to establish whether supplements of VitD could prevent TB infections (49) .
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